Retrospective Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 14, 2023; 29(22): 3508-3518
Published online Jun 14, 2023. doi: 10.3748/wjg.v29.i22.3508
Efficacy and safety of modified tetracycline dosing in a quadruple therapy for Helicobacter pylori: A retrospective single center study
Ying-Chao Sun, Meng-Jia Zhu, Xue-Qin Chen, Lei Yue, Yi-Ru Zhao, Xin-Jie Wang, John J Kim, Qin Du, Wei-Ling Hu
Ying-Chao Sun, Meng-Jia Zhu, Xue-Qin Chen, Lei Yue, Yi-Ru Zhao, Xin-Jie Wang, Wei-Ling Hu, Department of Gastroenterology, Sir Run Run Shaw Hospital, Medical School, Zhejiang University, Hangzhou 310016, Zhejiang Province, China
John J Kim, Division of Gastroenterology, Loma Linda University Health, Loma Linda, CA 92354, United States
Qin Du, Department of Gastroenterology, Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou 310009, Zhejiang Province, China
Wei-Ling Hu, Institute of Gastroenterology, Zhejiang University, Hangzhou 310016, Zhejiang Province, China
Author contributions: Yingchao Sun, Mengjia Zhu and Xueqin Chen have contributed equally to this work. Sun YC and Hu WL contributed to conceptualization; Sun YC and Wang XJ contributed to writing-original draft preparation; Zhu MJ and Yue L contributed to writing; Chen XQ, Zhao YR, and Zhu MJ contributed to review and editing; Kim JJ contributed to manuscript polishing; Hu WL contributed to supervision; and all authors have read and agreed to the published version of the manuscript.
Supported by the Zhejiang Provincial Natural Science Foundation, No. LY23H160016; and Zhejiang Medical Association, No. 2019ZYC-A88.
Institutional review board statement: This study was reviewed and approved by the Institutional Review Board of Sir Run Run Shaw Hospital, Medical School, Zhejiang University, Hangzhou (Approval No. SRRSH: 2022-431).
Informed consent statement: Patient consent was waived due the impossibility of identifying patients and the retrospective design of the investigation.
Conflict-of-interest statement: The authors declare no conflict of interest.
Data sharing statement: The datasets generated and/or analyzed during the current study are not publicly available but are available from the corresponding author upon reasonable request.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wei-Ling Hu, MD, Doctor, Department of Gastroenterology, Sir Run Run Shaw Hospital, Medical School, Zhejiang University, No. 3 East Qingchun Road, Hangzhou 310016, Zhejiang Province, China. huweiling@zju.edu.cn
Received: March 28, 2023
Peer-review started: March 28, 2023
First decision: April 26, 2023
Revised: May 9, 2023
Accepted: May 15, 2023
Article in press: May 15, 2023
Published online: June 14, 2023
Core Tip

Core Tip: To our knowledge, this is the first real-world study to evaluate the efficacy and safety of modified dosing of tetracycline as part of tetracycline and furazolidone-containing bismuth quadruple therapy in patients with Helicobacter pylori infection.